Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse.
Evalyn E A P MulderIva JohanssonDirk J van GrünhagenDennie TempelBarbara Rentroia-PachecoJvalini T DwarkasingDaniëlle VerverAntien L MooyaartAstrid A M van der VeldtMarlies WakkeeTamar E C NijstenCornelis VerhoefJan MattssonLars NyLoes M HollesteinRoger Olofsson BaggePublished in: Cancers (2022)
In these two independent European cohorts, the CP-GEP model was able to stratify patients with stage I-II melanoma into two groups differentiated by RFS.